首页 | 本学科首页   官方微博 | 高级检索  
     


A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer
Authors:Bora Lim  Juhee Song  Nuhad K. Ibrahim  Kimberly B. Koenig  Mariana Chavez-MacGregor  Joe E. Ensor Jr  Jill Schwartz Gomez  Savitri Krishnamurthy  Abigail S. Caudle  Simona F. Shaitelman  Gary J. Whitman  Vicente Valero
Affiliation:1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Methodist Research Institute, Houston, Texas, USA;4. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;5. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;7. Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract:
Keywords:Eribulin  Paclitaxel  HER2-negative  Breast cancer  Neoadjuvant chemotherapy
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号